题名

顯微鏡下的新視野：初探癌症免疫細胞治療與照護困境

并列篇名

New Horizons Under the Microscope: Exploring the Challenges of Cancer immune cell therapy and Care

DOI

10.6692/KJN.202408_41(2).0002

作者

陳品蓉(Pin-Jung Chen)；卓士峯(Shih-Feng Cho)；阮瓊慧(Chiung-Hui Juan)；李秀嬌(Hsiu-Chiao Li)；王彣瑄(Wen-Hsuan Wang)；陳怡伶(I-Lin Chen)；張芳綾(Fang-Ling Chang)

关键词

癌症 ； 免疫細胞治療 ； 護理照護 ； Cancer ； immune cell therapy ； nursing care

期刊名称

高雄護理雜誌

卷期/出版年月

41卷2期（2024 / 08 / 01）

页次

13 - 22

内容语文

繁體中文;英文
中文摘要

免疫細胞治療是用生物技術培育人體免疫細胞作為治療方式，將身體原有細胞分離出來，在外人工增殖後再注射回體內去攻擊腫瘤。台灣的細胞治療尚處於發展中，對癌症病患來說是新增治療選項，但就臨床實務上，仍有許多議題須逐一克服，包含細胞製劑管理流程與品質監控、輸注流程、照護重點與作業規範或其倫理課題備受挑戰；在照護過程中，護理人員需因應劃時代治療，來滿足以病人為中心的照護，其學習的躍進仍需雙向轉動；因此，本文是探討癌症病患初次接受免疫細胞治療於臨床實務時所面臨之現況，提出分析與討論，期許增進癌症病患可近性、連續性的全人照護。
英文摘要

Immune cell therapy is a biotechnology-based treatment modality that involves the culture of human immune cells, in which the native cells are isolated from the body, cultured ex vivo to expand their population, and subsequently reintroduced into the human body to mount an anti-tumor response. Although cell therapy is still in its developmental stage in Taiwan, it represents a new treatment option for cancer patients. However, there are still numerous clinical issues that need to be addressed, including cell preparation and quality control, infusion protocols, nursing priorities and operational standards, as well as ethical challenges. In the care process, nurses need to adapt to this revolutionary treatment to provide patient-centered care, and their learning process requires a two-way exchange. Therefore, this article evaluates the current situation of cancer patients receiving immune cell therapy for the first time in clinical practice, and proposes analysis and discussion to improve the accessibility and continuity of comprehensive care for cancer patients.
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. 范麗娟（2010）．符合公平正義之福利經費規劃：以台灣兒少與老人福利支出爲例．國家與社會9，33-65。https://doi.org/10.30174/jss.201012.0002
    連結：
  2. 羅彗君、沈雯琪（2021）．晚期癌症病人接受不同攝食途徑營養照護後營養相關指標變化之比較．台灣營養學會雜誌，45（2），44-56。https://doi.org/10.6691/nsj.202106_45(2).0002
    連結：
  3. Avigan, D. (2004). Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10(18 Pt 2), 6347-6352. https://doi.org/10.1158/1078-0432.CCR-050005
    連結：
  4. Fan, J., Shang, D., Han, B., Song, J., Chen, H., & Yang, J. M. (2018). Adoptive cell transfer: Is it a promising immunotherapy for colorectal cancer? Theranostics, 8(20), 5784-5800. https://doi.org/10.7150/thno.29035
    連結：
  5. Garofano, F., Gonzalez-Carmona, M. A., Skowasch, D., Schmidt-Wolf, R., Abramian, A., Hauser, S., Strassburg, C. P., & Schmidt-Wolf, I. G. H. (2019). Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy. International Journal of Molecular Sciences, 20(17), 4307. https://doi.org/10.3390/ijms20174307
    連結：
  6. Guo, Y., & Han, W. (2015). Cytokine-induced killer (CIK) cells: From basic research to clinical translation. Chinese Journal of Cancer, 34(3), 99-107. https://doi.org/10.1186/s40880-015-0002-1
    連結：
  7. Handy, C. E., & Antonarakis, E. S. (2018). Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions. Future Oncology (London, England), 14(10), 907-917. https://doi.org/10.2217/fon-2017-0531
    連結：
  8. Kang, B. H., & Lee, H. K. (2022). Dendritic Cell-Based immunotherapy in hot and cold tumors. International Journal of Molecular Sciences, 23(13), 7325. https://doi.org/10.3390/ijms23137325
    連結：
  9. Madan, R. A., Antonarakis, E. S., Drake, C. G., Fong, L., Yu, E. Y., McNeel, D. G., Lin, D. W., Chang, N. N., Sheikh, N. A., & Gulley, J. L. (2020). Putting the pieces together: Completing the mechanism of action jigsaw for Sipuleucel-T. Journal of the National Cancer Institute, 112(6), 562-573. https://doi.org/10.1093/jnci/djaa021
    連結：
  10. Miller, L. J., Douglas, C., McCullough, F. S., Stanworth, S. J., & Calder, P. C. (2022). Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials. Clinical Nutrition (Edinburgh, Scotland), 41(10), 2135-2146. https://doi.org/10.1016/j.clnu.2022.07.039
    連結：
  11. Pang, Z., Wang, Z., Li, F., Feng, C., & Mu, X. (2022). Current progress of CAR-NK Therapy in cancer treatment. Cancers, 14(17), 4318. https://doi.org/10.3390/cancers14174318
    連結：
  12. Shi, Y., Men, X., Li, X., Yang, Z., & Wen, H. (2020). Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma. International Immunopharmacology, 82, 106351. https://doi.org/10.1016/j.intimp.2020.106351
    連結：
  13. Tarannum, M., & Romee, R. (2021). Cytokine-induced memory-like natural killer cells for cancer immunotherapy. Stem Cell Research & Therapy, 12(1), 592. https://doi.org/10.1186/s13287-021-02655-5
    連結：
  14. Thanendrarajan, S., Nowak, M., Abken, H., & Schmidt-Wolf, I. G. H. (2011). Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? Leukemia Research, 35(9), 1136-1142. https://doi.org/10.1016/j.leukres.2011.05.005
    連結：
  15. Wolf, B., Zimmermann, S., Arber, C., Irving, M., Trueb, L., & Coukos, G. (2019). Safety and tolerability of adoptive cell therapy in cancer. Drug Safety, 42(2), 315-334. https://doi.org/10.1007/s40264-018-0779-3
    連結：
  16. Zhang, Y., & Schmidt-Wolf, I. G. H. (2020). Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. Journal of Cellular Physiology, 235(12), 9291-9303. https://doi.org/10.1002/jcp.29827
    連結：
  17. 高尚志、林致凡、劉雅芳（2020）．台灣特管辦法通過之免疫細胞治療．臺灣醫界，63（4），26-36。
  18. 張金堅（2019）．細胞治療於二十一世紀癌症治療的角色．臺灣醫界，62（12），13-22。
  19. 趙榮杰（2019）．免疫細胞療法治癌新進展．臺灣醫界，62（4），32-38。
  20. 衛生福利部（2021，2月9日）．修正「特定醫療技術檢查檢驗醫療儀器施行或使用管理辦法」（衛部醫字第1101660674號）。https://gazette.nat.gov.tw/egFront/detail.do?metaid=122004
print cancel